<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Bootsrap v5</title>
    <link rel="stylesheet" href="/css/main.css" />
    <link href="/css/carousel.css" rel="stylesheet">

</head>

<body class="d-flex flex-column sticky-footer-wrapper">
    <!-- Fixed navbar -->
       
    <header>
        <nav class="navbar navbar-expand-md fixed-top navbar-light" style="background-color: #e3f2fd;; padding: 0 8px; background-image: none; border-bottom: 1px dashed gray;border-top: 1px dashed gray; min-height: 55px;">
          <div class="container-fluid">
            <img style="height: 30px;" src="/images/logo.png" alt="Target2035">
            <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarCollapse" aria-controls="navbarCollapse" aria-expanded="false" aria-label="Toggle navigation">
              <span class="navbar-toggler-icon"></span>
            </button>
            <div class="collapse navbar-collapse nav-custom" id="navbarCollapse">
              <ul class="navbar-nav m-auto mb-2 mb-md-0">
                <li class="nav-item active">
                  <a class="nav-link" aria-current="page" href="/">Home</a>
              </li>
              <li class="nav-item">
                  <a class="nav-link" href="/contributors.html">Contributing</a>
              </li>
      
              <li class="nav-item">
                  <a class="nav-link" href="/strategy.html">Strategy</a>
              </li>
      
              <li class="nav-item">
                  <a class="nav-link" href="/whitepaper.html">White paper</a>
              </li>
              <li class="nav-item">
                  <a class="nav-link" href="/readmore.html">Read more</a>
              </li>
              <li class="nav-item">
                  <a class="nav-link" href="/webinars.html">Monthly Webinars</a>
              </li>
              <li class="nav-item">
                  <a class="nav-link" href="/archives.html">Archive</a>
              </li>
              <li class="nav-item">
                  <a class="nav-link" href="/faq.html">FAQ</a>
              </li>
              <li class="nav-item">
                  <a class="nav-link" href="/contact.html">Contact</a>
              </li>
              </ul>
            </div>
          </div>
        </nav>
    </header>
    

    <!-- Begin page content -->
    <main class="flex-shrink-0">
        <div class="container mt-5">
            <div class="row">
                <div class="post">
                        <h2>Chemical Probes </h2>
                        <p>A chemical probe is a compound that selectively modulates the activity of a single protein (or a small group of closely related proteins) in cells at reasonable concentrations (< 1 micromolar), i.e., it is potent, selective and cell active.</p>
                        <p>Target2035 probes are peer reviewed, and hosted on <Link> Chemical Portal.</p>
                            <div class="row m-5">
                                <div class="text-center"><h4>Chemical Probe Stories</h4></div>
                                <div class="text-center">  <img style="height: 250px;" src="/images/wdr5.png" alt="wdr5"> </div>
                                <div class="text-center"> <h5>WDR5 chemical probe: From published probe to preclinical program in 5 years</h5> </div>
                            </div>
                        <p>The chemical probe OICR-9429, an inhibitor of WDR5, is an excellent example how published probes can impact preclinical research. WDR5, a member of the WD40 subfamily, is a component of several chromatin regulatory complexes including the MLL1 (Mixed Lineage Leukemia 1) complex.</p>
                        <p>In 2014, the collaboration between the SGC and The Drug Discovery Program at the Ontario Institute for Cancer Research (OICR) culminated in the discovery and publication of OICR-9429. Further optimization by Triphase Accelerator, a Toronto based oncology-focused drug-development company, resulted in TRPH-395.</p>
                        <p>In 2019, Celgene purchased the rights for preclinical program with TPRH-395 as a preclinical drug candidate for treating blood cancers, including leukemia.</p>
                        <div class="text-center m-5">  <img style="height: 250px;" src="/images/oicr.png" alt="wdr5"> </div>

                        <div class="row probe">
                            <div class="col"> 
                                <p>2006 - 2014​</p> 
                                <p>Increasing relevance of ​</p> 
                                <p>WDR disease association</p> 
                            </div>
                            <div class="col"> 
                                <p>2006 - 2014​</p> 
                                <p>Increasing relevance of ​</p> 
                                <p>WDR disease association</p> 
                            </div>
                            <div class="col"> 
                                <p>2019​</p> 
                                <p>Celgene purchased rights​</p> 
                                <p>for preclinical program</p> 
                            </div>
                        </div>

                        <div class="row m-5">
                            <div class="col"> <img style="height: 250px;"  src="/images/structure1.png" alt=""> </div>
                            <div class="col"> <img style="height: 250px;"  src="/images/structure2.png" alt=""> </div>
                        </div>

                        <div class="mb-5"></div>

                </div>
            </div>
        </div>
    </main>

    <!-- Begin footer -->
    <footer class="footer mt-auto py-3">
        <div class="container-fluid">
            <div class="row text-center m-5">
                <div class="col">
                    <h1>
                        <a class="navbar-brand" href="/">Target 2035</a>
                    </h1>
                    <span> <a href="mailto:target2035@thesgc.org">target2035@thesgc.org</a></span>
                </div>
                
                <div class="col">
                    <p>
Target 2035 website is licensed under a <a href="https://creativecommons.org/licenses/by/4.0">CC-BY</a> licence  | <a href="http://target2035.loc/accessibility">Accessibility</a>  
                    </p>
                </div>
            </div>
        </div>
    </footer>
    <script src="/js/bootstrap.bundle.min.js"></script>

</body>

</html>